Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07116746 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment reduced: 25 → 15 participantsv5 Show 4 more changesShow less
    • Trial status changed: Recruiting → Active, Not Recruiting
    • Primary completion pushed from Jul 2026 to Nov 2026
    • Study completion pushed from Jan 2027 to Feb 2027
    • Site details revised at 8 of 8 sites
  2. Study sites: 4 to 8v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 4
    • Start date changed from estimate of Sep 2025 to Dec 3, 2025
    v3
  4. Study title shortened, about 8 wordsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will assess the effect of AR882 and XOI co-administration on sUA lowering as well as reducing tophus burden in the population that has failed uricase treatment (eg., pegloticase). Failed uricase treatment is defined as having an inherent intolerance, anaphylaxis, infusion reaction, antibody development, and/or at least one sUA level that rose to greater than 6 mg/dL while on therapy.
Trial Details
NCT Number NCT07116746
Lead Sponsor Arthrosi Therapeutics
Conditions
(from sponsor)		 Gout, Gouty Arthritis, Hyperuricemia, Gout Chronic, Refractory Gout, Uncontrolled Gout, Tophaceous Gout
Related terms Arthritis, Gouty, Gout, Hyperuricemia
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov